S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B

JSON

Tobiasson M, Pandzic T, Illman J, Nilsson L, Weström S, Sollander K, Ejerblad E, Olsnes Kittang A, Olesen G, Werlenius O, Björklund A, Wiggh J, lindholm C, Lorentz F, Rasmussen B, Cammenga J, Weber D, Grönnås D, Dimitriou M, Kytölä S, Walldin G, Ljungman P, Groenbeck K, Mielke S, Jacobsen SE, Ebeling F, Cavelier L, Smidstrup Friis L, Dybedal I, Hellström-Lindberg E

Hemasphere 6 (-) 68-69 [2022-06-00; online 2022-06-23]

DOI 10.1097/01.hs9.0000843560.87168.a9

Crossref 10.1097/01.hs9.0000843560.87168.a9